This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

10 Cheap Biotech Stocks That Could Soar

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player


GTx management has a lot of experience in the prostate cancer field. Unfortunately, the company's collective know-how hasn't prevented a series of damaging drug development blow-ups from occurring.

But GTx is persistent, so the company is now focused on capesaris, an experimental testosterone deprivation therapy for prostate cancer patients. A phase IIb study comparing daily, oral capesaris to an every-three-month injection of Lupron was started this month, with results possible at the end of the year or early in 2012. GTx is developing capesaris to have equivalent efficacy to Lupron, the current standard of care for hormone-dependent prostate cancer patients, but with a better tolerability and side effect profile.

If the capesaris data from the phase IIb study are positive, a pivotal phase III study could start in the middle of 2012.

9 of 11

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
ASTM $3.62 0.84%
CLSN $2.89 1.05%
CYCC $0.97 -3.96%
DSCI $8.61 2.50%
GTXI $0.71 -2.46%


DOW 17,949.59 -85.34 -0.47%
S&P 500 2,097.29 -3.11 -0.15%
NASDAQ 5,014.1020 +19.50 0.39%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs